semaglutide deaths Recent reports link around 10 and 100 hospitalizations in the U.S. to compounded versions of semaglutide, sold under the brand name Ozempic by Novo Nordisk. The company has raised concerns with Special Collection: Obesity Findings and
Description
If documentation supports a detailed code and you use a general one, that is undercoding, and it costs your practice money

Messier SP, et al
Additionally, the introduction of Wegovy, an FDA-approved higher-dose version of Ozempic, intended to treat obesity, raises concerns about potential adverse effects

No, GLP-1 receptor agonists are not licensed or recommended for treating IBS

You're committing to giving the protocol a fair trial, not to a contractual obligation
